Cleveland BioLabs Submits Response To Department Of Defense Request For Proposal For Radiation Countermeasure

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that it has submitted a response to the Request for Proposal (RFP) issued by The Department of Defense (DoD) for the advanced development, Food and Drug Administration (FDA) approval/licensure and delivery of Medical Radiation Countermeasure (MRC). In a statement to the press, Michael Fonstein, Ph.D…

More: continued here

Filed under: Radiology on March 1st, 2010